Overview

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Status:
Recruiting
Trial end date:
2024-08-20
Target enrollment:
Participant gender:
Summary
This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Cyclophosphamide
Doxorubicin
Pembrolizumab
Prednisone
Vincristine